GC Cell is a Korea-based biotech with proven success in commercial cell therapy and a robust pipeline of allogeneic NK and CAR-NK programs. Our autologous CIK therapy (Immuncell-LC) is approved in Korea as an adjuvant for early-stage HCC, with over 10,000 patients treated. We are seeking global/regional partners to expand its reach.

Our allogeneic CD5 CAR-NK (GCC2005) is in Phase 1 for PTCL, with patient dosing ongoing—DL1 and DL2 results are to be orally presented during ASH2025 with preliminary efficacy showing 60% ORR (40% CR, 20%PR) at low-dose cohorts. We are actively seeking global partners.

HER2 CAR-NK (GCC2003) is planned to enter Phase 1 IIT in Q2 2026, and is also open for global partnering.

With 16+ years of GMP experience and a 20,806m² facility, we also offer integrated CDMO services from development to commercial-scale manufacturing.

Let’s explore how we can collaborate to advance innovative cell therapies together.